COVID-19 Vaccines: Regulation, Allocation, & Hesitancy
COVID-19 Vaccines: Regulation, Allocation, & Hesitancy
This explainer is more than 90 days old. Some of the information might be out of date or no longer relevant. Browse our homepage for up to date content or request information about a specific topic from our team of scientists.
This article has been translated from its original language. Please reach out if you have any feedback on the translation.
With several COVID-19 vaccines now making their way toward marketing approval, a number of difficult questions loom. Who should have access to the first available doses? How will companies and regulators assess safety and efficacy, including over the long term? And what does research say about the best ways for public health experts—and journalists—to communicate about the benefits and risks of COVID-19 vaccination? SciLine's on-the-record briefing addressed these issues and provided journalists with an opportunity to ask questions.
With several COVID-19 vaccines now making their way toward marketing approval, a number of difficult questions loom. Who should have access to the first available doses? How will companies and regulators assess safety and efficacy, including over the long term? And what does research say about the best ways for public health experts—and journalists—to communicate about the benefits and risks of COVID-19 vaccination? SciLine's on-the-record briefing addressed these issues and provided journalists with an opportunity to ask questions.
